Top-Thema

19.07.19
ROUNDUP/Aktien New York Schluss: Schwächer - Sorgen um Konflikt mit Iran

Viking Therapeutics to Present at Biotech Showcase 2019

Mittwoch, 02.01.2019 13:30 von PR Newswire

PR Newswire

SAN DIEGO, Jan. 2, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation at the 11th Annual Biotech Showcase, being held January 7-9, 2019 at the Hilton San Francisco Union Square in San Francisco. 

Viking Therapeutics

Details for this presentation are as follows:

Dax: Zwischenbilanz zum Halbjahr

Im ersten Halbjahr 2019 zeigten sich die meisten DAX®-Aktien in Gewinnerlaune. Welche Aktien und Themen für das zweite Halbjahr spannend werden erfahrt ihr hier!

  • Biotech Showcase 2019 – webcast available
    Time/Date: 11:30 a.m. PT on Monday, January 7, 2019
    Location: Hilton San Francisco Union Square
    Room: Yosemite C

To access the live webcast of Viking's presentation, please visit "Webcasts & Presentations" within the News & Events section of Viking's Investors page at www.vikingtherapeutics.com. Additionally, a replay of the webcast will be available on the Viking website following the conference.

About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.  The company's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives.  The company's clinical programs include VK2809, a small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, including non-alcoholic steatohepatitis (NASH).  In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content. VK2809 was shown to be safe and well-tolerated in the study.  The company is also developing VK0214, a small molecule selective thyroid hormone receptor beta agonist for the treatment of X-linked adrenoleukodystrophy.  The company's other programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator.  In a Phase 2 trial in patients recovering from hip fracture, patients who received VK5211 experienced significant improvements in measures of lean body mass compared to patients who received placebo.  Other programs also include VK0612, a first-in-class, orally available drug candidate in Phase 2 development for the treatment of type 2 diabetes as well as two earlier-stage programs targeting metabolic diseases and anemia.  Viking holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

Follow Viking on Twitter @Viking_VKTX.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/viking-therapeutics-to-present-at-biotech-showcase-2019-300771590.html

SOURCE Viking Therapeutics, Inc.

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.